The DOI matches its Crossref record.
In interleukin‐4‐deficient mice, alum not only generates T helper 1 responses equivalent to Freund's complete adjuvant, but continues to induce T helper 2 cytokine production
Abstract
The role of interleukin (IL)‐4 in the activity of two frequently used vaccine adjuvants, Freund's complete adjuvant (FCA) and the aluminum hydroxide gels (alum), was studied using the standard antigen ovalbumin (OVA) in IL‐4 genedisrupted mice (IL‐4 ‐/‐). In the absence of adjuvant, there was an overall reduction in antibody production to OVA in IL‐4 −/− mice and significantly greater amounts of interferon (IFN)‐γ were produced following restimulation of splenocytes with antigen in vitro compared with immunocompetent controls (IL‐4 +/+). FCA and alum boosted the immune response to OVA in both IL‐4 −/− and IL‐4 +/+ mice. In IL‐4 +/+ mice, while FCA stimulated a wide‐spectrum immunoglobulin response, including both Th1‐associated IgG2a and Th2‐associated IgG1, alum enhanced only Th2 antibody production and no OVA‐specific IgG2a could be detected. In IL‐4‐deficient mice, however, not only was IgG2a production increased in all adjuvant‐treated groups, but alum was as potent at stimulating this antibody subclass as FCA. Similarly, increased production in vitro by splenocytes of the Th1 cytokine IFN‐γ, equivalent to that produced after inoculation with FCA/OVA, was only detected in IL‐4 −/− mice inoculated with alum/OVA. There was no IgE production in IL‐4 −/− mice and OVA‐specific IgG1 production, although still at significant levels, was reduced compared with wild‐type mice irrespective of the adjuvant used. However, although production of the Th2 cytokine IL‐5 was totally inhibited in IL‐4‐deficient mice inoculated with FCA/OVA, there was no significant difference in IL‐5 production between the two strains when alum was used as adjuvant.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Emerging concepts in the science of vaccine adjuvants
Pulendran, B., S. Arunachalam, P., & O’Hagan, D. T. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00163-y · Cited by 1,385
Vaccine adjuvants: Current state and future trends
Petrovsky, N., & Aguilar, J. C. (2004) · Immunology & Cell Biology · doi:10.1111/j.0818-9641.2004.01272.x · Cited by 1,005
Kool, M., Soullié, T., van Nimwegen, M., Willart, M. A. M., Muskens, F., Jung, S., Hoogsteden, H. C., Hammad, H., & Lambrecht, B. N. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20071087 · Cited by 993
Towards an understanding of the adjuvant action of aluminium
Marrack, P., McKee, A. S., & Munks, M. W. (2009) · Nature Reviews Immunology · doi:10.1038/nri2510 · Cited by 887
Aguilar, J. C., & Rodríguez, E. G. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.01.111 · Cited by 494
Aluminium compounds for use in vaccines
Lindblad, E. B. (2004) · Immunology & Cell Biology · doi:10.1111/j.0818-9641.2004.01286.x · Cited by 488
Brewer, J. M., Conacher, M., Hunter, C. A., Mohrs, M., Brombacher, F., & Alexander, J. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.12.6448 · Cited by 440
Self-citationMechanism of Immunopotentiation and Safety of Aluminum Adjuvants
HogenEsch, H. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00406 · Cited by 430
Impaired Development of Th2 Cells in IL-13-Deficient Mice
McKenzie, G. J., Emson, C. L., Bell, S. E., Anderson, S., Fallon, P., Zurawski, G., Murray, R., Grencis, R., & McKenzie, A. N. J. (1998) · Immunity · doi:10.1016/s1074-7613(00)80625-1 · Cited by 381
Aluminium adjuvants—in retrospect and prospect
Lindblad, E. B. (2004) · Vaccine · doi:10.1016/j.vaccine.2004.03.032 · Cited by 362
Mechanisms of stimulation of the immune response by aluminum adjuvants
HogenEsch, H. (2002) · Vaccine · doi:10.1016/s0264-410x(02)00169-x · Cited by 354
Mechanism of action of clinically approved adjuvants
Lambrecht, B. N., Kool, M., Willart, M. A., & Hammad, H. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.01.004 · Cited by 354
Immunological concepts of vaccine adjuvant activity
Schijns, V. E. (2000) · Current Opinion in Immunology · doi:10.1016/s0952-7915(00)00120-5 · Cited by 330
Akdis (2020) · doi:10.1111/pai.13189 · Cited by 320
Alum adjuvant: some of the tricks of the oldest adjuvant
Kool, M., Fierens, K., & Lambrecht, B. N. (2012) · Journal of Medical Microbiology · doi:10.1099/jmm.0.038943-0 · Cited by 318
Akimoto, T., Numata, F., Tamura, M., Takata, Y., Higashida, N., Takashi, T., Takeda, K., & Akira, S. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.9.1537 · Cited by 304
Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosis
Kaufmann, S. H. E., & McMichael, A. J. (2005) · Nature Medicine · doi:10.1038/nm1221 · Cited by 273
How Do Adjuvants Work? Important Considerations for New Generation Adjuvants
McKee, A. S., Munks, M. W., & Marrack, P. (2007) · Immunity · doi:10.1016/j.immuni.2007.11.003 · Cited by 263
Okano, M., Satoskar, A. R., Nishizaki, K., & Harn, D. A. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.1.442 · Cited by 210
Self-citationSmith, K. M., Pottage, L., Thomas, E. R., Leishman, A. J., Doig, T. N., Xu, D., Liew, F. Y., & Garside, P. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.6.3136 · Cited by 185
Metadata
- Authors
- Brewer, J. M., Conacher, M., Satoskar, A., Bluethmann, H., & Alexander, J.
- Venue
- European Journal of Immunology
- Publisher
- Wiley
- Published
- 1996-09
- Volume
- 26
- Issue
- 9
- Pages
- 2062-2066
- ISSN
- 0014-2980 (ISSN-L)
- 1521-4141
- OpenAlex
- W2005788144
- Cited by
- 232
- References
- 0
- FWCI
- 2.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.